Carotid Artery Diseases
|
group |
Nervous System Diseases; Cardiovascular Diseases
|
Disease or Syndrome
|
69
|
6
|
0.010 |
None |
1.000 |
1 |
1
|
2009 |
2009 |
Diabetes Mellitus
|
group |
Nutritional and Metabolic Diseases; Endocrine System Diseases
|
Disease or Syndrome
|
2803
|
824
|
0.010 |
None |
1.000 |
1 |
|
2014 |
2014 |
nervous system disorder
|
group |
Nervous System Diseases
|
Disease or Syndrome
|
977
|
39
|
0.010 |
None |
1.000 |
1 |
|
2015 |
2015 |
Psychotic Disorders
|
group |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
560
|
179
|
0.310 |
None |
< 0.001 |
1 |
|
2011 |
2011 |
B-Cell Lymphomas
|
group |
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
1408
|
42
|
0.010 |
None |
1.000 |
1 |
|
2011 |
2011 |
Prion Diseases
|
group |
Infections; Nervous System Diseases
|
Disease or Syndrome
|
175
|
67
|
0.100 |
None |
1.000 |
1 |
1
|
2012 |
2012 |
Dyslipidemias
|
group |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
471
|
184
|
0.310 |
None |
1.000 |
1 |
|
2018 |
2018 |
Parkinsonian Disorders
|
group |
Nervous System Diseases
|
Disease or Syndrome
|
373
|
95
|
0.110 |
None |
1.000 |
1 |
|
2016 |
2016 |
Lipids measurement
|
group |
|
Laboratory Procedure
|
27
|
53
|
0.100 |
None |
1.000 |
1 |
1
|
2013 |
2013 |
Chronic Kidney Diseases
|
group |
Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases
|
Disease or Syndrome
|
1074
|
306
|
0.010 |
None |
1.000 |
1 |
1
|
2014 |
2014 |
Language Disorders
|
group |
Pathological Conditions, Signs and Symptoms; Nervous System Diseases
|
Mental or Behavioral Dysfunction
|
94
|
25
|
0.100 |
None |
|
0 |
|
|
|
Intellectual Disability
|
group |
Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Mental Disorders; Behavior and Behavior Mechanisms
|
Mental or Behavioral Dysfunction
|
2165
|
159
|
0.100 |
None |
|
0 |
|
|
|
Low density lipoprotein cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
483
|
1142
|
0.100 |
None |
1.000 |
11 |
6
|
2008 |
2019 |
Serum LDL cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
269
|
555
|
0.100 |
None |
1.000 |
7 |
4
|
2008 |
2013 |
C-reactive protein measurement
|
phenotype |
|
Laboratory Procedure
|
135
|
624
|
0.100 |
None |
1.000 |
6 |
5
|
2008 |
2019 |
Serum total cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
486
|
1243
|
0.100 |
None |
1.000 |
6 |
6
|
2009 |
2019 |
Triglycerides measurement
|
phenotype |
|
Laboratory Procedure
|
563
|
1418
|
0.100 |
None |
1.000 |
5 |
5
|
2012 |
2019 |
High density lipoprotein measurement
|
phenotype |
|
Laboratory Procedure
|
545
|
1440
|
0.100 |
None |
1.000 |
5 |
5
|
2009 |
2019 |
Body mass index
|
phenotype |
|
Clinical Attribute
|
1014
|
2689
|
0.100 |
None |
1.000 |
5 |
1
|
2015 |
2019 |
Mental deterioration
|
phenotype |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
508
|
121
|
0.130 |
None |
1.000 |
4 |
4
|
2014 |
2017 |
Serum HDL cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
283
|
679
|
0.100 |
None |
1.000 |
3 |
2
|
2009 |
2013 |
Longevity
|
phenotype |
|
Temporal Concept
|
48
|
74
|
0.100 |
None |
1.000 |
2 |
1
|
2011 |
2012 |
Cognitive changes
|
phenotype |
Pathological Conditions, Signs and Symptoms; Nervous System Diseases
|
Mental or Behavioral Dysfunction
|
50
|
15
|
0.020 |
None |
0.500 |
2 |
|
2011 |
2019 |
Body mass index procedure
|
phenotype |
|
Diagnostic Procedure
|
88
|
252
|
0.100 |
None |
1.000 |
1 |
1
|
2013 |
2013 |
Hypertriglyceridemia
|
phenotype |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
340
|
169
|
0.010 |
None |
1.000 |
1 |
1
|
2015 |
2015 |